메뉴 건너뛰기




Volumn 124, Issue 22, 2018, Pages 4301-4313

Erratum to: Toward the potential cure of leukemias in the next decade: Toward the Cure of Leukemias (Cancer, (2018), 124, 22, (4301-4313), 10.1002/cncr.31669);Toward the potential cure of leukemias in the next decade

Author keywords

cure; leukemias; targeted; therapy; treatments

Indexed keywords

ALPHA INTERFERON; ANTHRACYCLINE; ARSENIC TRIOXIDE; AZACITIDINE; BLINATUMOMAB; CLADRIBINE; CLOFARABINE; CYCLOPHOSPHAMIDE; CYTARABINE; DASATINIB; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; HOMOHARRINGTONINE; IBRUTINIB; IDARUBICIN; IMATINIB; INOTUZUMAB OZOGAMICIN; IVOSIDENIB; METHOTREXATE; OBINUTUZUMAB; PENTOSTATIN; PONATINIB; RETINOIC ACID; RITUXIMAB; UNINDEXED DRUG; VENETOCLAX; VINCRISTINE; ANTINEOPLASTIC AGENT;

EID: 85054547845     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.31966     Document Type: Erratum
Times cited : (44)

References (173)
  • 1
    • 85015285314 scopus 로고    scopus 로고
    • Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia
    • Grever MR, Abdel-Wahab O, Andritsos LA, et al. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood. 2017;129:553-560
    • (2017) Blood , vol.129 , pp. 553-560
    • Grever, M.R.1    Abdel-Wahab, O.2    Andritsos, L.A.3
  • 2
    • 84892637595 scopus 로고    scopus 로고
    • Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: a single-institution series
    • Rosenberg JD, Burian C, Waalen J, Saven A. Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: a single-institution series. Blood. 2014;123:177-183
    • (2014) Blood , vol.123 , pp. 177-183
    • Rosenberg, J.D.1    Burian, C.2    Waalen, J.3    Saven, A.4
  • 3
    • 28044446541 scopus 로고    scopus 로고
    • Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years
    • Else M, Ruchlemer R, Osuji N, et al. Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years. Cancer. 2005;104:2442-2448
    • (2005) Cancer , vol.104 , pp. 2442-2448
    • Else, M.1    Ruchlemer, R.2    Osuji, N.3
  • 4
    • 0345689335 scopus 로고    scopus 로고
    • Rituximab in relapsed or refractory hairy cell leukemia
    • Thomas DA, O'Brien S, Bueso-Ramos C, et al. Rituximab in relapsed or refractory hairy cell leukemia. Blood. 2003;102:3906-3911
    • (2003) Blood , vol.102 , pp. 3906-3911
    • Thomas, D.A.1    O'Brien, S.2    Bueso-Ramos, C.3
  • 5
    • 80053649383 scopus 로고    scopus 로고
    • Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia
    • Ravandi F, O'Brien S, Jorgensen J, et al. Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia. Blood. 2011;118:3818-3823
    • (2011) Blood , vol.118 , pp. 3818-3823
    • Ravandi, F.1    O'Brien, S.2    Jorgensen, J.3
  • 6
    • 84987720558 scopus 로고    scopus 로고
    • Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial
    • Chihara D, Kantarjian H, O'Brien S, et al. Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial. Br J Haematol. 2016;174:760-766
    • (2016) Br J Haematol , vol.174 , pp. 760-766
    • Chihara, D.1    Kantarjian, H.2    O'Brien, S.3
  • 7
    • 77958510339 scopus 로고    scopus 로고
    • Acute promyelocytic leukaemia: novel insights into the mechanisms of cure
    • de The H, Chen Z. Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat Rev Cancer. 2010;10:775-783
    • (2010) Nat Rev Cancer , vol.10 , pp. 775-783
    • de The, H.1    Chen, Z.2
  • 8
    • 61949441174 scopus 로고    scopus 로고
    • Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
    • Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2009;113:1875-1891
    • (2009) Blood , vol.113 , pp. 1875-1891
    • Sanz, M.A.1    Grimwade, D.2    Tallman, M.S.3
  • 9
    • 0023752982 scopus 로고
    • Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia
    • Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 1988;72:567-572
    • (1988) Blood , vol.72 , pp. 567-572
    • Huang, M.E.1    Ye, Y.C.2    Chen, S.R.3
  • 10
    • 0030610687 scopus 로고    scopus 로고
    • 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients
    • 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997;89:3354-3360
    • (1997) Blood , vol.89 , pp. 3354-3360
    • Shen, Z.X.1    Chen, G.Q.2    Ni, J.H.3
  • 11
    • 79955991053 scopus 로고    scopus 로고
    • AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance
    • Avvisati G, Lo-Coco F, Paoloni FP, et al. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. Blood. 2011;117:4716-4725
    • (2011) Blood , vol.117 , pp. 4716-4725
    • Avvisati, G.1    Lo-Coco, F.2    Paoloni, F.P.3
  • 12
    • 77958499078 scopus 로고    scopus 로고
    • Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group
    • Lo-Coco F, Avvisati G, Vignetti M, et al. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. Blood. 2010;116:3171-3179
    • (2010) Blood , vol.116 , pp. 3171-3179
    • Lo-Coco, F.1    Avvisati, G.2    Vignetti, M.3
  • 13
    • 0037115195 scopus 로고    scopus 로고
    • All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol
    • Tallman MS, Andersen JW, Schiffer CA, et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood. 2002;100:4298-4302
    • (2002) Blood , vol.100 , pp. 4298-4302
    • Tallman, M.S.1    Andersen, J.W.2    Schiffer, C.A.3
  • 14
    • 0035884639 scopus 로고    scopus 로고
    • United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia
    • Soignet SL, Frankel SR, Douer D, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001;19:3852-3860
    • (2001) J Clin Oncol , vol.19 , pp. 3852-3860
    • Soignet, S.L.1    Frankel, S.R.2    Douer, D.3
  • 15
    • 77958456360 scopus 로고    scopus 로고
    • Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710
    • Powell BL, Moser B, Stock W, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood. 2010;116:3751-3757
    • (2010) Blood , vol.116 , pp. 3751-3757
    • Powell, B.L.1    Moser, B.2    Stock, W.3
  • 16
    • 84865427746 scopus 로고    scopus 로고
    • All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)
    • quiz 1752
    • Iland HJ, Bradstock K, Supple SG, et al. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood. 2012;120:1570-1580; quiz 1752
    • (2012) Blood , vol.120 , pp. 1570-1580
    • Iland, H.J.1    Bradstock, K.2    Supple, S.G.3
  • 17
    • 79960225126 scopus 로고    scopus 로고
    • Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia
    • Ghavamzadeh A, Alimoghaddam K, Rostami S, et al. Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. J Clin Oncol. 2011;29:2753-2757
    • (2011) J Clin Oncol , vol.29 , pp. 2753-2757
    • Ghavamzadeh, A.1    Alimoghaddam, K.2    Rostami, S.3
  • 18
    • 77956251955 scopus 로고    scopus 로고
    • Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data
    • Mathews V, George B, Chendamarai E, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. J Clin Oncol. 2010;28:3866-3871
    • (2010) J Clin Oncol , vol.28 , pp. 3866-3871
    • Mathews, V.1    George, B.2    Chendamarai, E.3
  • 19
    • 0036625070 scopus 로고    scopus 로고
    • Experience with gemtuzumab ozogamycin (”Mylotarg“) and all-trans retinoic acid in untreated acute promyelocytic leukemia
    • Estey EH, Giles FJ, Beran M, et al. Experience with gemtuzumab ozogamycin (”Mylotarg“) and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood. 2002;99:4222-4224
    • (2002) Blood , vol.99 , pp. 4222-4224
    • Estey, E.H.1    Giles, F.J.2    Beran, M.3
  • 20
    • 33646386643 scopus 로고    scopus 로고
    • Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia
    • Estey E, Garcia-Manero G, Ferrajoli A, et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood. 2006;107:3469-3473
    • (2006) Blood , vol.107 , pp. 3469-3473
    • Estey, E.1    Garcia-Manero, G.2    Ferrajoli, A.3
  • 21
    • 59149089411 scopus 로고    scopus 로고
    • Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin
    • Ravandi F, Estey E, Jones D, et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol. 2009;27:504-510
    • (2009) J Clin Oncol , vol.27 , pp. 504-510
    • Ravandi, F.1    Estey, E.2    Jones, D.3
  • 22
    • 85015251442 scopus 로고    scopus 로고
    • Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab
    • Abaza Y, Kantarjian H, Garcia-Manero G, et al. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood. 2017;129:1275-1283
    • (2017) Blood , vol.129 , pp. 1275-1283
    • Abaza, Y.1    Kantarjian, H.2    Garcia-Manero, G.3
  • 23
    • 84880287051 scopus 로고    scopus 로고
    • Retinoic acid and arsenic trioxide for acute promyelocytic leukemia
    • Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369:111-121
    • (2013) N Engl J Med , vol.369 , pp. 111-121
    • Lo-Coco, F.1    Avvisati, G.2    Vignetti, M.3
  • 24
    • 85013070481 scopus 로고    scopus 로고
    • Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 Trial
    • Platzbecker U, Avvisati G, Cicconi L, et al. Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 Trial. J Clin Oncol. 2017;35:605-612
    • (2017) J Clin Oncol , vol.35 , pp. 605-612
    • Platzbecker, U.1    Avvisati, G.2    Cicconi, L.3
  • 25
    • 84948978098 scopus 로고    scopus 로고
    • Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial
    • Burnett AK, Russell NH, Hills RK, et al. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2015;16:1295-1305
    • (2015) Lancet Oncol , vol.16 , pp. 1295-1305
    • Burnett, A.K.1    Russell, N.H.2    Hills, R.K.3
  • 26
    • 84055213176 scopus 로고    scopus 로고
    • Oral arsenic trioxide-based maintenance regimens for first complete remission of acute promyelocytic leukemia: a 10-year follow-up study
    • Au WY, Kumana CR, Lee HK, et al. Oral arsenic trioxide-based maintenance regimens for first complete remission of acute promyelocytic leukemia: a 10-year follow-up study. Blood. 2011;118:6535-6543
    • (2011) Blood , vol.118 , pp. 6535-6543
    • Au, W.Y.1    Kumana, C.R.2    Lee, H.K.3
  • 27
    • 84892940228 scopus 로고    scopus 로고
    • Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial
    • Zhu HH, Wu DP, Jin J, et al. Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial. J Clin Oncol. 2013;31:4215-4221
    • (2013) J Clin Oncol , vol.31 , pp. 4215-4221
    • Zhu, H.H.1    Wu, D.P.2    Jin, J.3
  • 28
    • 84869502214 scopus 로고    scopus 로고
    • Acute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975-2008
    • Chen Y, Kantarjian H, Wang H, Cortes J, Ravandi F. Acute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975-2008. Cancer. 2012;118:5811-5818
    • (2012) Cancer , vol.118 , pp. 5811-5818
    • Chen, Y.1    Kantarjian, H.2    Wang, H.3    Cortes, J.4    Ravandi, F.5
  • 29
    • 68949137224 scopus 로고    scopus 로고
    • Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy
    • Grimwade D, Jovanovic JV, Hills RK, et al. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol. 2009;27:3650-3658
    • (2009) J Clin Oncol , vol.27 , pp. 3650-3658
    • Grimwade, D.1    Jovanovic, J.V.2    Hills, R.K.3
  • 30
    • 4644288302 scopus 로고    scopus 로고
    • Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup
    • Schlenk RF, Benner A, Krauter J, et al. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol. 2004;22:3741-3750
    • (2004) J Clin Oncol , vol.22 , pp. 3741-3750
    • Schlenk, R.F.1    Benner, A.2    Krauter, J.3
  • 31
    • 24944464648 scopus 로고    scopus 로고
    • Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv: a Cancer and Leukemia Group B study
    • Marcucci G, Mrozek K, Ruppert AS, et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv: a Cancer and Leukemia Group B study. J Clin Oncol. 2005;23:5705-5717
    • (2005) J Clin Oncol , vol.23 , pp. 5705-5717
    • Marcucci, G.1    Mrozek, K.2    Ruppert, A.S.3
  • 32
    • 33748747555 scopus 로고    scopus 로고
    • The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations
    • Appelbaum FR, Kopecky KJ, Tallman MS, et al. The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations. Br J Haematol. 2006;135:165-173
    • (2006) Br J Haematol , vol.135 , pp. 165-173
    • Appelbaum, F.R.1    Kopecky, K.J.2    Tallman, M.S.3
  • 33
    • 58149220896 scopus 로고    scopus 로고
    • Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival
    • Borthakur G, Kantarjian H, Wang X, et al. Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival. Cancer. 2008;113:3181-3185
    • (2008) Cancer , vol.113 , pp. 3181-3185
    • Borthakur, G.1    Kantarjian, H.2    Wang, X.3
  • 34
    • 79952099282 scopus 로고    scopus 로고
    • Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial
    • Burnett AK, Hills RK, Milligan D, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol. 2011;29:369-377
    • (2011) J Clin Oncol , vol.29 , pp. 369-377
    • Burnett, A.K.1    Hills, R.K.2    Milligan, D.3
  • 35
    • 84881305790 scopus 로고    scopus 로고
    • A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
    • Petersdorf SH, Kopecky KJ, Slovak M, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013;121:4854-4860
    • (2013) Blood , vol.121 , pp. 4854-4860
    • Petersdorf, S.H.1    Kopecky, K.J.2    Slovak, M.3
  • 36
    • 84908053861 scopus 로고    scopus 로고
    • Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia
    • Borthakur G, Cortes JE, Estey EE, et al. Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia. Am J Hematol. 2014;89:964-968
    • (2014) Am J Hematol , vol.89 , pp. 964-968
    • Borthakur, G.1    Cortes, J.E.2    Estey, E.E.3
  • 37
    • 84867297401 scopus 로고    scopus 로고
    • Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial
    • Yin JA, O'Brien MA, Hills RK, Daly SB, Wheatley K, Burnett AK. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. Blood. 2012;120:2826-2835
    • (2012) Blood , vol.120 , pp. 2826-2835
    • Yin, J.A.1    O'Brien, M.A.2    Hills, R.K.3    Daly, S.B.4    Wheatley, K.5    Burnett, A.K.6
  • 38
    • 77957287616 scopus 로고    scopus 로고
    • Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia
    • Corbacioglu A, Scholl C, Schlenk RF, et al. Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia. J Clin Oncol. 2010;28:3724-3729
    • (2010) J Clin Oncol , vol.28 , pp. 3724-3729
    • Corbacioglu, A.1    Scholl, C.2    Schlenk, R.F.3
  • 39
    • 85020460570 scopus 로고    scopus 로고
    • Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia
    • Ragon BK, Daver N, Garcia-Manero G, et al. Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia. Am J Hematol. 2017;92:845-850
    • (2017) Am J Hematol , vol.92 , pp. 845-850
    • Ragon, B.K.1    Daver, N.2    Garcia-Manero, G.3
  • 40
    • 77950612017 scopus 로고    scopus 로고
    • Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML
    • Pollard JA, Alonzo TA, Gerbing RB, et al. Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. Blood. 2010;115:2372-2379
    • (2010) Blood , vol.115 , pp. 2372-2379
    • Pollard, J.A.1    Alonzo, T.A.2    Gerbing, R.B.3
  • 41
    • 33748467435 scopus 로고    scopus 로고
    • Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv and t(8;21): a Cancer and Leukemia Group B study
    • Paschka P, Marcucci G, Ruppert AS, et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv and t(8;21): a Cancer and Leukemia Group B study. J Clin Oncol. 2006;24:3904-3911
    • (2006) J Clin Oncol , vol.24 , pp. 3904-3911
    • Paschka, P.1    Marcucci, G.2    Ruppert, A.S.3
  • 42
    • 0038170400 scopus 로고    scopus 로고
    • Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias
    • Care RS, Valk PJ, Goodeve AC, et al. Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. Br J Haematol. 2003;121:775-777
    • (2003) Br J Haematol , vol.121 , pp. 775-777
    • Care, R.S.1    Valk, P.J.2    Goodeve, A.C.3
  • 43
    • 33344465478 scopus 로고    scopus 로고
    • KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival
    • Schnittger S, Kohl TM, Haferlach T, et al. KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood. 2006;107:1791-1799
    • (2006) Blood , vol.107 , pp. 1791-1799
    • Schnittger, S.1    Kohl, T.M.2    Haferlach, T.3
  • 44
    • 33646432204 scopus 로고    scopus 로고
    • Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study
    • Cairoli R, Beghini A, Grillo G, et al. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood. 2006;107:3463-3468
    • (2006) Blood , vol.107 , pp. 3463-3468
    • Cairoli, R.1    Beghini, A.2    Grillo, G.3
  • 45
    • 33744487375 scopus 로고    scopus 로고
    • Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML)
    • Boissel N, Leroy H, Brethon B, et al. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia. 2006;20:965-970
    • (2006) Leukemia , vol.20 , pp. 965-970
    • Boissel, N.1    Leroy, H.2    Brethon, B.3
  • 46
    • 84948678259 scopus 로고    scopus 로고
    • Chapter 133. Chronic myeloid leukemia
    • KasperD, FauciA, HauserS, LongoD, JamesonJ, LoscalzoJ, eds., New York, McGraw-Hill
    • Kantarjian H, Cortes J. Chapter 133. Chronic myeloid leukemia. In: Kasper D, Fauci A, Hauser S, Longo D, Jameson J, Loscalzo J, eds. Harrison's Principles of Internal Medicine. New York: McGraw-Hill; 2014:687-695
    • (2014) Harrison's Principles of Internal Medicine , pp. 687-695
    • Kantarjian, H.1    Cortes, J.2
  • 47
    • 84944591667 scopus 로고    scopus 로고
    • Chapter 101. Chronic myeloid leukemia
    • NiederhuberJE, ArmitageJO, DoroshowJH, KastanMB, TepperJE, eds., Philadelphia, PA, Elsevier Churchill Livingstone
    • Kantarjian H, Cortes J. Chapter 101. Chronic myeloid leukemia. In: Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE, eds. Abeloff's Clinical Oncology. Philadelphia, PA: Elsevier Churchill Livingstone; 2014:1944
    • (2014) Abeloff's Clinical Oncology , pp. 1944
    • Kantarjian, H.1    Cortes, J.2
  • 48
    • 85059045982 scopus 로고    scopus 로고
    • Chronic myelogenous leukemia
    • ProvanD, GribbenJG, eds., 3rd ed, Oxford, UK, Wiley-Blackwell, In Press 8/2018
    • Kantarjian H, Cortes J, Jabbour E, O'Brien S. Chronic myelogenous leukemia. In: Provan D, Gribben JG, eds. Molecular Hematology. 3rd ed. Oxford, UK: Wiley-Blackwell; In Press 8/2018
    • Molecular Hematology
    • Kantarjian, H.1    Cortes, J.2    Jabbour, E.3    O'Brien, S.4
  • 49
    • 85041416695 scopus 로고    scopus 로고
    • Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring
    • Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring. Am J Hematol. 2018;93:442-459
    • (2018) Am J Hematol , vol.93 , pp. 442-459
    • Jabbour, E.1    Kantarjian, H.2
  • 51
    • 85048250671 scopus 로고    scopus 로고
    • Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial
    • Cortes JE, Kim DW, Pinilla-Ibarz J, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018;132:393-404
    • (2018) Blood , vol.132 , pp. 393-404
    • Cortes, J.E.1    Kim, D.W.2    Pinilla-Ibarz, J.3
  • 52
    • 84897573995 scopus 로고    scopus 로고
    • Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease
    • Rousselot P, Charbonnier A, Cony-Makhoul P, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol. 2014;32:424-430
    • (2014) J Clin Oncol , vol.32 , pp. 424-430
    • Rousselot, P.1    Charbonnier, A.2    Cony-Makhoul, P.3
  • 53
    • 85015700652 scopus 로고    scopus 로고
    • Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study
    • Hochhaus A, Masszi T, Giles FJ, et al. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. Leukemia. 2017;31:1525-1531
    • (2017) Leukemia , vol.31 , pp. 1525-1531
    • Hochhaus, A.1    Masszi, T.2    Giles, F.J.3
  • 54
    • 78049528573 scopus 로고    scopus 로고
    • Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
    • Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11:1029-1035
    • (2010) Lancet Oncol , vol.11 , pp. 1029-1035
    • Mahon, F.X.1    Rea, D.2    Guilhot, J.3
  • 55
    • 84977624843 scopus 로고    scopus 로고
    • Moving treatment-free remission into mainstream clinical practice in CML
    • Hughes TP, Ross DM. Moving treatment-free remission into mainstream clinical practice in CML. Blood. 2016;128:17-23
    • (2016) Blood , vol.128 , pp. 17-23
    • Hughes, T.P.1    Ross, D.M.2
  • 56
  • 57
    • 0001656646 scopus 로고    scopus 로고
    • Chapter 134. Malignancies of lymphoid cells
    • KasperD, FauciA, HauserS, LongoD, JamesonJ, LoscalzoJ, eds., New York, McGraw-Hill
    • Longo DL. Chapter 134. Malignancies of lymphoid cells. In: Kasper D, Fauci A, Hauser S, Longo D, Jameson J, Loscalzo J, eds. Harrison's Principles of Internal Medicine. New York: McGraw-Hill; 2014:695-710
    • Harrison's Principles of Internal Medicine , vol.2014 , pp. 695-710
    • Longo, D.L.1
  • 58
    • 45149100665 scopus 로고    scopus 로고
    • Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
    • Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446-5456
    • (2008) Blood , vol.111 , pp. 5446-5456
    • Hallek, M.1    Cheson, B.D.2    Catovsky, D.3
  • 59
    • 0025239350 scopus 로고
    • Effects of chlorambucil and therapeutic decision in initial forms of chronic lymphocytic leukemia (stage A): results of a randomized clinical trial on 612 patients. The French Cooperative Group on Chronic Lymphocytic Leukemia
    • Effects of chlorambucil and therapeutic decision in initial forms of chronic lymphocytic leukemia (stage A): results of a randomized clinical trial on 612 patients. The French Cooperative Group on Chronic Lymphocytic Leukemia. Blood. 1990;75:1414-1421
    • (1990) Blood , vol.75 , pp. 1414-1421
  • 60
    • 84958181962 scopus 로고    scopus 로고
    • Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia
    • Thompson PA, Tam CS, O'Brien SM, et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood. 2016;127:303-309
    • (2016) Blood , vol.127 , pp. 303-309
    • Thompson, P.A.1    Tam, C.S.2    O'Brien, S.M.3
  • 61
    • 84955482904 scopus 로고    scopus 로고
    • Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial
    • Fischer K, Bahlo J, Fink AM, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016;127:208-215
    • (2016) Blood , vol.127 , pp. 208-215
    • Fischer, K.1    Bahlo, J.2    Fink, A.M.3
  • 62
    • 85034832329 scopus 로고    scopus 로고
    • FCR achieves long-term durable remissions in patients with IGHV-mutated CLL
    • Chai-Adisaksopha C, Brown JR. FCR achieves long-term durable remissions in patients with IGHV-mutated CLL. Blood. 2017;130:2278-2282
    • (2017) Blood , vol.130 , pp. 2278-2282
    • Chai-Adisaksopha, C.1    Brown, J.R.2
  • 63
    • 0024216099 scopus 로고
    • Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia
    • Grever MR, Kopecky KJ, Coltman CA, et al. Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia. Nouv Rev Fr Hematol. 1988;30:457-459
    • (1988) Nouv Rev Fr Hematol , vol.30 , pp. 457-459
    • Grever, M.R.1    Kopecky, K.J.2    Coltman, C.A.3
  • 64
    • 0024319910 scopus 로고
    • Fludarabine: a new agent with major activity against chronic lymphocytic leukemia
    • Keating MJ, Kantarjian H, Talpaz M, et al. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood. 1989;74:19-25
    • (1989) Blood , vol.74 , pp. 19-25
    • Keating, M.J.1    Kantarjian, H.2    Talpaz, M.3
  • 65
    • 33745942111 scopus 로고    scopus 로고
    • Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2)
    • Robak T, Blonski JZ, Gora-Tybor J, et al. Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2). Blood. 2006;108:473-479
    • (2006) Blood , vol.108 , pp. 473-479
    • Robak, T.1    Blonski, J.Z.2    Gora-Tybor, J.3
  • 66
    • 77951628255 scopus 로고    scopus 로고
    • Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study)
    • Robak T, Jamroziak K, Gora-Tybor J, et al. Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study). J Clin Oncol. 2010;28:1863-1869
    • (2010) J Clin Oncol , vol.28 , pp. 1863-1869
    • Robak, T.1    Jamroziak, K.2    Gora-Tybor, J.3
  • 67
    • 0034649696 scopus 로고    scopus 로고
    • Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia
    • Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000;343:1750-1757
    • (2000) N Engl J Med , vol.343 , pp. 1750-1757
    • Rai, K.R.1    Peterson, B.L.2    Appelbaum, F.R.3
  • 68
    • 23044510136 scopus 로고    scopus 로고
    • Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia
    • Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23:4079-4088
    • (2005) J Clin Oncol , vol.23 , pp. 4079-4088
    • Keating, M.J.1    O'Brien, S.2    Albitar, M.3
  • 69
    • 79954435811 scopus 로고    scopus 로고
    • Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB Study 9712
    • Woyach JA, Ruppert AS, Heerema NA, et al. Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB Study 9712. J Clin Oncol. 2011;29:1349-1355
    • (2011) J Clin Oncol , vol.29 , pp. 1349-1355
    • Woyach, J.A.1    Ruppert, A.S.2    Heerema, N.A.3
  • 70
    • 0035889147 scopus 로고    scopus 로고
    • Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients
    • Leporrier M, Chevret S, Cazin B, et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood. 2001;98:2319-2325
    • (2001) Blood , vol.98 , pp. 2319-2325
    • Leporrier, M.1    Chevret, S.2    Cazin, B.3
  • 71
    • 31544434508 scopus 로고    scopus 로고
    • Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia
    • Eichhorst BF, Busch R, Hopfinger G, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood. 2006;107:885-891
    • (2006) Blood , vol.107 , pp. 885-891
    • Eichhorst, B.F.1    Busch, R.2    Hopfinger, G.3
  • 72
    • 33947541773 scopus 로고    scopus 로고
    • Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997
    • Flinn IW, Neuberg DS, Grever MR, et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol. 2007;25:793-798
    • (2007) J Clin Oncol , vol.25 , pp. 793-798
    • Flinn, I.W.1    Neuberg, D.S.2    Grever, M.R.3
  • 73
    • 34447530283 scopus 로고    scopus 로고
    • Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial
    • Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet. 2007;370:230-239
    • (2007) Lancet , vol.370 , pp. 230-239
    • Catovsky, D.1    Richards, S.2    Matutes, E.3
  • 74
    • 77957664665 scopus 로고    scopus 로고
    • Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
    • Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376:1164-1174
    • (2010) Lancet , vol.376 , pp. 1164-1174
    • Hallek, M.1    Fischer, K.2    Fingerle-Rowson, G.3
  • 75
    • 84866531516 scopus 로고    scopus 로고
    • Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group
    • Fischer K, Cramer P, Busch R, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2012;30:3209-3216
    • (2012) J Clin Oncol , vol.30 , pp. 3209-3216
    • Fischer, K.1    Cramer, P.2    Busch, R.3
  • 76
    • 84924378553 scopus 로고    scopus 로고
    • Frontline chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) shows superior efficacy in comparison to bendamustine (B) and rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): final analysis of an international, randomized study of the German CLL Study Group (GCLLSG) (CLL10 Study) [abstract]
    • Eichhorst B, Fink AM, Busch R, et al. Frontline chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) shows superior efficacy in comparison to bendamustine (B) and rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): final analysis of an international, randomized study of the German CLL Study Group (GCLLSG) (CLL10 Study) [abstract]. Blood. 2014;21:19
    • (2014) Blood , vol.21 , pp. 19
    • Eichhorst, B.1    Fink, A.M.2    Busch, R.3
  • 77
    • 84906855910 scopus 로고    scopus 로고
    • Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study
    • Burger JA, Keating MJ, Wierda WG, et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2014;15:1090-1099
    • (2014) Lancet Oncol , vol.15 , pp. 1090-1099
    • Burger, J.A.1    Keating, M.J.2    Wierda, W.G.3
  • 78
    • 84896441354 scopus 로고    scopus 로고
    • The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) monotherapy demonstrates long-term safety and durability of response in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) patients in an open-label extension study [abstract]
    • O'Brien S, Furman RR, Fowler F, et al. The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) monotherapy demonstrates long-term safety and durability of response in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) patients in an open-label extension study [abstract]. Blood. 2013;122:4163
    • (2013) Blood , vol.122 , pp. 4163
    • O'Brien, S.1    Furman, R.R.2    Fowler, F.3
  • 79
    • 84879748062 scopus 로고    scopus 로고
    • Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia
    • Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32-42
    • (2013) N Engl J Med , vol.369 , pp. 32-42
    • Byrd, J.C.1    Furman, R.R.2    Coutre, S.E.3
  • 80
    • 84904252369 scopus 로고    scopus 로고
    • Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia
    • Byrd JC, Brown JR, O'Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371:213-223
    • (2014) N Engl J Med , vol.371 , pp. 213-223
    • Byrd, J.C.1    Brown, J.R.2    O'Brien, S.3
  • 81
    • 84891373281 scopus 로고    scopus 로고
    • Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial
    • O'Brien S, Furman RR, Coutre SE, et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol. 2014;15:48-58
    • (2014) Lancet Oncol , vol.15 , pp. 48-58
    • O'Brien, S.1    Furman, R.R.2    Coutre, S.E.3
  • 82
    • 84955481177 scopus 로고    scopus 로고
    • Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia
    • Byrd JC, Harrington B, O'Brien S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:323-332
    • (2016) N Engl J Med , vol.374 , pp. 323-332
    • Byrd, J.C.1    Harrington, B.2    O'Brien, S.3
  • 83
    • 84896692766 scopus 로고    scopus 로고
    • Idelalisib and rituximab in relapsed chronic lymphocytic leukemia
    • Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370:997-1007
    • (2014) N Engl J Med , vol.370 , pp. 997-1007
    • Furman, R.R.1    Sharman, J.P.2    Coutre, S.E.3
  • 84
    • 84955491187 scopus 로고    scopus 로고
    • Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia
    • Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:311-322
    • (2016) N Engl J Med , vol.374 , pp. 311-322
    • Roberts, A.W.1    Davids, M.S.2    Pagel, J.M.3
  • 85
    • 85051555432 scopus 로고    scopus 로고
    • A multicenter, phase II study of ibrutinib plus FCR (iFCR) as frontline therapy for younger CLL patients [abstract]
    • Davids MS, Kim HT, Brander DM, et al. A multicenter, phase II study of ibrutinib plus FCR (iFCR) as frontline therapy for younger CLL patients [abstract]. Blood. 2017;130(suppl 1):496
    • (2017) Blood , vol.130 , pp. 496
    • Davids, M.S.1    Kim, H.T.2    Brander, D.M.3
  • 86
    • 85046105712 scopus 로고    scopus 로고
    • Venetoclax plus rituximab is superior to bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia—results from pre-planned interim analysis of the randomized phase 3 Murano study [abstract]
    • Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax plus rituximab is superior to bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia—results from pre-planned interim analysis of the randomized phase 3 Murano study [abstract]. Blood. 2017;130(suppl 1):LBA-2
    • (2017) Blood , vol.130 , pp. LBA-2
    • Seymour, J.F.1    Kipps, T.J.2    Eichhorst, B.3
  • 87
    • 85045051546 scopus 로고    scopus 로고
    • Combined venetoclax and ibrutinib for patients with previously untreated high-risk CLL, and relapsed/refractory CLL: a phase II trial [abstract]
    • Jain N, Thompson PA, Ferrajoli A, et al. Combined venetoclax and ibrutinib for patients with previously untreated high-risk CLL, and relapsed/refractory CLL: a phase II trial [abstract]. Blood. 2017;130(suppl 1):429
    • (2017) Blood , vol.130 , pp. 429
    • Jain, N.1    Thompson, P.A.2    Ferrajoli, A.3
  • 88
    • 84937523007 scopus 로고    scopus 로고
    • New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia
    • Jabbour E, O'Brien S, Konopleva M, Kantarjian H. New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia. Cancer. 2015;121:2517-2528
    • (2015) Cancer , vol.121 , pp. 2517-2528
    • Jabbour, E.1    O'Brien, S.2    Konopleva, M.3    Kantarjian, H.4
  • 89
    • 84978224232 scopus 로고    scopus 로고
    • Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Munster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen
    • Rytting ME, Jabbour EJ, Jorgensen JL, et al. Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Munster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen. Am J Hematol. 2016;91:819-823
    • (2016) Am J Hematol , vol.91 , pp. 819-823
    • Rytting, M.E.1    Jabbour, E.J.2    Jorgensen, J.L.3
  • 90
    • 85016336607 scopus 로고    scopus 로고
    • Acute lymphoblastic leukemia in adolescents and young adults
    • Rytting ME, Jabbour EJ, O'Brien SM, Kantarjian HM. Acute lymphoblastic leukemia in adolescents and young adults. Cancer. 2017;123:2398-2403
    • (2017) Cancer , vol.123 , pp. 2398-2403
    • Rytting, M.E.1    Jabbour, E.J.2    O'Brien, S.M.3    Kantarjian, H.M.4
  • 91
    • 84969916695 scopus 로고    scopus 로고
    • Genomic profiling of adult and pediatric B-cell acute lymphoblastic leukemia
    • Liu YF, Wang BY, Zhang WN, et al. Genomic profiling of adult and pediatric B-cell acute lymphoblastic leukemia. EBioMedicine. 2016;8:173-183
    • (2016) EBioMedicine , vol.8 , pp. 173-183
    • Liu, Y.F.1    Wang, B.Y.2    Zhang, W.N.3
  • 92
    • 84907187094 scopus 로고    scopus 로고
    • Outcomes of children with BCR-ABL1-like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease
    • Roberts KG, Pei D, Campana D, et al. Outcomes of children with BCR-ABL1-like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease. J Clin Oncol. 2014;32:3012-3020
    • (2014) J Clin Oncol , vol.32 , pp. 3012-3020
    • Roberts, K.G.1    Pei, D.2    Campana, D.3
  • 93
    • 85033556924 scopus 로고    scopus 로고
    • Philadelphia chromosome-like acute lymphoblastic leukemia
    • Tasian SK, Loh ML, Hunger SP. Philadelphia chromosome-like acute lymphoblastic leukemia. Blood. 2017;130:2064-2072
    • (2017) Blood , vol.130 , pp. 2064-2072
    • Tasian, S.K.1    Loh, M.L.2    Hunger, S.P.3
  • 94
    • 85014854171 scopus 로고    scopus 로고
    • Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults
    • Jain N, Roberts KG, Jabbour E, et al. Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults. Blood. 2017;129:572-581
    • (2017) Blood , vol.129 , pp. 572-581
    • Jain, N.1    Roberts, K.G.2    Jabbour, E.3
  • 95
    • 85016717027 scopus 로고    scopus 로고
    • High frequency and poor outcome of Philadelphia chromosome-like acute lymphoblastic leukemia in adults
    • Roberts KG, Gu Z, Payne-Turner D, et al. High frequency and poor outcome of Philadelphia chromosome-like acute lymphoblastic leukemia in adults. J Clin Oncol. 2017;35:394-401
    • (2017) J Clin Oncol , vol.35 , pp. 394-401
    • Roberts, K.G.1    Gu, Z.2    Payne-Turner, D.3
  • 96
    • 84975504780 scopus 로고    scopus 로고
    • MLL-rearranged acute lymphoblastic leukemias activate BCL-2 through H3K79 methylation and are sensitive to the BCL-2-specific antagonist ABT-199
    • Benito JM, Godfrey L, Kojima K, et al. MLL-rearranged acute lymphoblastic leukemias activate BCL-2 through H3K79 methylation and are sensitive to the BCL-2-specific antagonist ABT-199. Cell Rep. 2015;13:2715-2727
    • (2015) Cell Rep , vol.13 , pp. 2715-2727
    • Benito, J.M.1    Godfrey, L.2    Kojima, K.3
  • 97
    • 84906908026 scopus 로고    scopus 로고
    • Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199
    • Chonghaile TN, Roderick JE, Glenfield C, et al. Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. Cancer Discov. 2014;4:1074-1087
    • (2014) Cancer Discov , vol.4 , pp. 1074-1087
    • Chonghaile, T.N.1    Roderick, J.E.2    Glenfield, C.3
  • 98
    • 47849108085 scopus 로고    scopus 로고
    • What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies
    • Stock W, La M, Sanford B, et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood. 2008;112:1646-1654
    • (2008) Blood , vol.112 , pp. 1646-1654
    • Stock, W.1    La, M.2    Sanford, B.3
  • 99
    • 84927776117 scopus 로고    scopus 로고
    • Favorable outcomes for older adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL): early results of US Intergroup Trial C10403 [abstract]
    • Stock W, Luger S, Advani A, et al. Favorable outcomes for older adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL): early results of US Intergroup Trial C10403 [abstract]. Blood. 2014;124:796
    • (2014) Blood , vol.124 , pp. 796
    • Stock, W.1    Luger, S.2    Advani, A.3
  • 100
    • 60949101218 scopus 로고    scopus 로고
    • Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study
    • Huguet F, Leguay T, Raffoux E, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol. 2009;27:911-918
    • (2009) J Clin Oncol , vol.27 , pp. 911-918
    • Huguet, F.1    Leguay, T.2    Raffoux, E.3
  • 101
    • 84986537214 scopus 로고    scopus 로고
    • Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trial
    • Patel B, Kirkwood AA, Dey A, et al. Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trial. Leukemia. 2017;31:58-64
    • (2017) Leukemia , vol.31 , pp. 58-64
    • Patel, B.1    Kirkwood, A.A.2    Dey, A.3
  • 102
    • 84929148590 scopus 로고    scopus 로고
    • Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
    • Daver N, Thomas D, Ravandi F, et al. Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica. 2015;100:653-661
    • (2015) Haematologica , vol.100 , pp. 653-661
    • Daver, N.1    Thomas, D.2    Ravandi, F.3
  • 103
    • 77955884680 scopus 로고    scopus 로고
    • Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00
    • Bassan R, Rossi G, Pogliani EM, et al. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. J Clin Oncol. 2010;28:3644-3652
    • (2010) J Clin Oncol , vol.28 , pp. 3644-3652
    • Bassan, R.1    Rossi, G.2    Pogliani, E.M.3
  • 104
    • 70449711127 scopus 로고    scopus 로고
    • Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a Children's Oncology Group study
    • Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a Children's Oncology Group study. J Clin Oncol. 2009;27:5175-5181
    • (2009) J Clin Oncol , vol.27 , pp. 5175-5181
    • Schultz, K.R.1    Bowman, W.P.2    Aledo, A.3
  • 105
    • 84894066916 scopus 로고    scopus 로고
    • UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia
    • Fielding AK, Rowe JM, Buck G, et al. UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. Blood. 2014;123:843-850
    • (2014) Blood , vol.123 , pp. 843-850
    • Fielding, A.K.1    Rowe, J.M.2    Buck, G.3
  • 106
    • 84948576141 scopus 로고    scopus 로고
    • Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
    • Ravandi F, O'Brien SM, Cortes JE, et al. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2015;121:4158-4164
    • (2015) Cancer , vol.121 , pp. 4158-4164
    • Ravandi, F.1    O'Brien, S.M.2    Cortes, J.E.3
  • 107
    • 85031736366 scopus 로고    scopus 로고
    • US Intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL
    • Ravandi F, Othus M, O'Brien SM, et al. US Intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL. Blood Adv. 2016;1:250-259
    • (2016) Blood Adv , vol.1 , pp. 250-259
    • Ravandi, F.1    Othus, M.2    O'Brien, S.M.3
  • 108
    • 84981541240 scopus 로고    scopus 로고
    • Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL
    • Rousselot P, Coude MM, Gokbuget N, et al. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL. Blood. 2016;128:774-782
    • (2016) Blood , vol.128 , pp. 774-782
    • Rousselot, P.1    Coude, M.M.2    Gokbuget, N.3
  • 109
    • 84995684141 scopus 로고    scopus 로고
    • Multicenter total therapy Gimema LAL 1509 protocol for de novo adult Ph+ acute lymphoblastic leukemia (ALL) patients. updated results and refined genetic-based prognostic stratification [abstract]
    • Chiaretti S, Vitale A, Elia L, et al. Multicenter total therapy Gimema LAL 1509 protocol for de novo adult Ph+ acute lymphoblastic leukemia (ALL) patients. updated results and refined genetic-based prognostic stratification [abstract]. Blood. 2015;126:23
    • (2015) Blood , vol.126 , pp. 23
    • Chiaretti, S.1    Vitale, A.2    Elia, L.3
  • 110
    • 85044974436 scopus 로고    scopus 로고
    • Frontline hyper-CVAD plus ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: updated results of a phase II study [abstract]
    • Short NJ, Kantarjian H, Ravandi F, et al. Frontline hyper-CVAD plus ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: updated results of a phase II study [abstract]. J Clin Oncol. 2017;15(suppl):7013
    • (2017) J Clin Oncol , vol.15 , pp. 7013
    • Short, N.J.1    Kantarjian, H.2    Ravandi, F.3
  • 111
    • 84994427169 scopus 로고    scopus 로고
    • Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a propensity score analysis
    • Sasaki K, Jabbour EJ, Ravandi F, et al. Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a propensity score analysis. Cancer. 2016;122:3650-3656
    • (2016) Cancer , vol.122 , pp. 3650-3656
    • Sasaki, K.1    Jabbour, E.J.2    Ravandi, F.3
  • 112
    • 84961063499 scopus 로고    scopus 로고
    • Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study
    • Jabbour E, Kantarjian H, Ravandi F, et al. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol. 2015;16:1547-1555
    • (2015) Lancet Oncol , vol.16 , pp. 1547-1555
    • Jabbour, E.1    Kantarjian, H.2    Ravandi, F.3
  • 113
    • 85044930499 scopus 로고    scopus 로고
    • First report of the Gimema LAL1811 phase II prospective study of the combination of steroids with ponatinib as frontline therapy of elderly or unfit patients with Philadelphia chromosome-positive acute lymphoblastic leukemia [abstract]
    • Martinelli G, Piciocchi A, Papayannidis C, et al. First report of the Gimema LAL1811 phase II prospective study of the combination of steroids with ponatinib as frontline therapy of elderly or unfit patients with Philadelphia chromosome-positive acute lymphoblastic leukemia [abstract]. Blood. 2017;130(suppl 1):99
    • (2017) Blood , vol.130 , pp. 99
    • Martinelli, G.1    Piciocchi, A.2    Papayannidis, C.3
  • 114
    • 85026225911 scopus 로고    scopus 로고
    • Complete hematologic and molecular response in adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study
    • Martinelli G, Boissel N, Chevallier P, et al. Complete hematologic and molecular response in adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study. J Clin Oncol. 2017;35:1795-1802
    • (2017) J Clin Oncol , vol.35 , pp. 1795-1802
    • Martinelli, G.1    Boissel, N.2    Chevallier, P.3
  • 115
    • 85029514413 scopus 로고    scopus 로고
    • Safety and efficacy of blinatumomab in combination with a tyrosine kinase inhibitor for the treatment of relapsed Philadelphia chromosome-positive leukemia
    • Assi R, Kantarjian H, Short NJ, et al. Safety and efficacy of blinatumomab in combination with a tyrosine kinase inhibitor for the treatment of relapsed Philadelphia chromosome-positive leukemia. Clin Lymphoma Myeloma Leuk. 2017;17:897-901
    • (2017) Clin Lymphoma Myeloma Leuk , vol.17 , pp. 897-901
    • Assi, R.1    Kantarjian, H.2    Short, N.J.3
  • 116
    • 33645830511 scopus 로고    scopus 로고
    • Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia
    • Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006;106:1569-1580
    • (2006) Cancer , vol.106 , pp. 1569-1580
    • Thomas, D.A.1    Faderl, S.2    O'Brien, S.3
  • 117
    • 84919481075 scopus 로고    scopus 로고
    • Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial
    • Hoelzer D, Walewski J, Dohner H, et al. Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial. Blood. 2014;124:3870-3879
    • (2014) Blood , vol.124 , pp. 3870-3879
    • Hoelzer, D.1    Walewski, J.2    Dohner, H.3
  • 118
    • 84980000230 scopus 로고    scopus 로고
    • Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial
    • Ribrag V, Koscielny S, Bosq J, et al. Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387:2402-2411
    • (2016) Lancet , vol.387 , pp. 2402-2411
    • Ribrag, V.1    Koscielny, S.2    Bosq, J.3
  • 119
    • 77956240944 scopus 로고    scopus 로고
    • Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia
    • Thomas DA, O'Brien S, Faderl S, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol. 2010;28:3880-3889
    • (2010) J Clin Oncol , vol.28 , pp. 3880-3889
    • Thomas, D.A.1    O'Brien, S.2    Faderl, S.3
  • 120
    • 84988449072 scopus 로고    scopus 로고
    • Rituximab in B-lineage adult acute lymphoblastic leukemia
    • Maury S, Chevret S, Thomas X, et al. Rituximab in B-lineage adult acute lymphoblastic leukemia. N Engl J Med. 2016;375:1044-1053
    • (2016) N Engl J Med , vol.375 , pp. 1044-1053
    • Maury, S.1    Chevret, S.2    Thomas, X.3
  • 121
    • 85041121752 scopus 로고    scopus 로고
    • Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study
    • Kantarjian H, Ravandi F, Short NJ, et al. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2018;19:240-248
    • (2018) Lancet Oncol , vol.19 , pp. 240-248
    • Kantarjian, H.1    Ravandi, F.2    Short, N.J.3
  • 122
    • 84880574025 scopus 로고    scopus 로고
    • Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia
    • Kantarjian H, Thomas D, Jorgensen J, et al. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013;119:2728-2736
    • (2013) Cancer , vol.119 , pp. 2728-2736
    • Kantarjian, H.1    Thomas, D.2    Jorgensen, J.3
  • 123
    • 84926099033 scopus 로고    scopus 로고
    • Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
    • Topp MS, Gokbuget N, Stein AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16:57-66
    • (2015) Lancet Oncol , vol.16 , pp. 57-66
    • Topp, M.S.1    Gokbuget, N.2    Stein, A.S.3
  • 124
    • 85029142692 scopus 로고    scopus 로고
    • Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study
    • DeAngelo DJ, Stock W, Stein AS, et al. Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study. Blood Adv. 2017;1:1167-1180
    • (2017) Blood Adv , vol.1 , pp. 1167-1180
    • DeAngelo, D.J.1    Stock, W.2    Stein, A.S.3
  • 125
    • 85047575618 scopus 로고    scopus 로고
    • Blinatumomab for minimal residual disease in adults with B-precursor acute lymphoblastic leukemia
    • Gokbuget N, Dombret H, Bonifacio M, et al. Blinatumomab for minimal residual disease in adults with B-precursor acute lymphoblastic leukemia. Blood. 2018;131:1522-1531
    • (2018) Blood , vol.131 , pp. 1522-1531
    • Gokbuget, N.1    Dombret, H.2    Bonifacio, M.3
  • 126
    • 85014771892 scopus 로고    scopus 로고
    • Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia
    • Kantarjian H, Stein A, Gokbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376:836-847
    • (2017) N Engl J Med , vol.376 , pp. 836-847
    • Kantarjian, H.1    Stein, A.2    Gokbuget, N.3
  • 127
    • 84984677465 scopus 로고    scopus 로고
    • Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia
    • Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375:740-753
    • (2016) N Engl J Med , vol.375 , pp. 740-753
    • Kantarjian, H.M.1    DeAngelo, D.J.2    Stelljes, M.3
  • 128
    • 84933505636 scopus 로고    scopus 로고
    • Monoclonal antibodies in acute lymphoblastic leukemia
    • Jabbour E, O'Brien S, Ravandi F, Kantarjian H. Monoclonal antibodies in acute lymphoblastic leukemia. Blood. 2015;125:4010-4016
    • (2015) Blood , vol.125 , pp. 4010-4016
    • Jabbour, E.1    O'Brien, S.2    Ravandi, F.3    Kantarjian, H.4
  • 129
    • 84869145679 scopus 로고    scopus 로고
    • Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia
    • Kantarjian H, Thomas D, Wayne AS, O'Brien S. Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia. J Clin Oncol. 2012;30:3876-3883
    • (2012) J Clin Oncol , vol.30 , pp. 3876-3883
    • Kantarjian, H.1    Thomas, D.2    Wayne, A.S.3    O'Brien, S.4
  • 130
    • 85045950102 scopus 로고    scopus 로고
    • Salvage chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD for patients with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: a phase 2 clinical trial
    • Jabbour E, Ravandi F, Kebriaei P, et al. Salvage chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD for patients with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: a phase 2 clinical trial. JAMA Oncol. 2018;4:230-234
    • (2018) JAMA Oncol , vol.4 , pp. 230-234
    • Jabbour, E.1    Ravandi, F.2    Kebriaei, P.3
  • 131
    • 85041428116 scopus 로고    scopus 로고
    • Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
    • Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439-448
    • (2018) N Engl J Med , vol.378 , pp. 439-448
    • Maude, S.L.1    Laetsch, T.W.2    Buechner, J.3
  • 132
    • 85041377767 scopus 로고    scopus 로고
    • Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia
    • Park JH, Riviere I, Gonen M, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378:449-459
    • (2018) N Engl J Med , vol.378 , pp. 449-459
    • Park, J.H.1    Riviere, I.2    Gonen, M.3
  • 133
    • 85010219668 scopus 로고    scopus 로고
    • Toward individualized therapy in acute myeloid leukemia: a contemporary review
    • Kadia TM, Ravandi F, Cortes J, Kantarjian H. Toward individualized therapy in acute myeloid leukemia: a contemporary review. JAMA Oncol. 2015;1:820-828
    • (2015) JAMA Oncol , vol.1 , pp. 820-828
    • Kadia, T.M.1    Ravandi, F.2    Cortes, J.3    Kantarjian, H.4
  • 134
    • 84954304674 scopus 로고    scopus 로고
    • Acute myeloid leukemia—major progress over 4 decades and glimpses into the future
    • Kantarjian H. Acute myeloid leukemia—major progress over 4 decades and glimpses into the future. Am J Hematol. 2016;91:131-145
    • (2016) Am J Hematol , vol.91 , pp. 131-145
    • Kantarjian, H.1
  • 136
    • 70349467775 scopus 로고    scopus 로고
    • Anthracycline dose intensification in acute myeloid leukemia
    • Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009;361:1249-1259
    • (2009) N Engl J Med , vol.361 , pp. 1249-1259
    • Fernandez, H.F.1    Sun, Z.2    Yao, X.3
  • 137
    • 70349451999 scopus 로고    scopus 로고
    • High-dose daunorubicin in older patients with acute myeloid leukemia
    • Lowenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009;361:1235-1248
    • (2009) N Engl J Med , vol.361 , pp. 1235-1248
    • Lowenberg, B.1    Ossenkoppele, G.J.2    van Putten, W.3
  • 138
    • 0027941369 scopus 로고
    • Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B
    • Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med. 1994;331:896-903
    • (1994) N Engl J Med , vol.331 , pp. 896-903
    • Mayer, R.J.1    Davis, R.B.2    Schiffer, C.A.3
  • 139
    • 10244249096 scopus 로고    scopus 로고
    • A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study
    • Weick JK, Kopecky KJ, Appelbaum FR, et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood. 1996;88:2841-2851
    • (1996) Blood , vol.88 , pp. 2841-2851
    • Weick, J.K.1    Kopecky, K.J.2    Appelbaum, F.R.3
  • 140
    • 9044228414 scopus 로고    scopus 로고
    • A randomized study of high-dose cytarabine in induction in acute myeloid leukemia
    • Bishop JF, Matthews JP, Young GA, et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood. 1996;87:1710-1717
    • (1996) Blood , vol.87 , pp. 1710-1717
    • Bishop, J.F.1    Matthews, J.P.2    Young, G.A.3
  • 141
    • 84932615484 scopus 로고    scopus 로고
    • 2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients
    • 2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood. 2015;125:3878-3885
    • (2015) Blood , vol.125 , pp. 3878-3885
    • Burnett, A.K.1    Russell, N.H.2    Hills, R.K.3
  • 142
    • 0005040904 scopus 로고    scopus 로고
    • A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. AML Collaborative Group
    • A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. AML Collaborative Group. Br J Haematol. 1998;103:100-109
    • (1998) Br J Haematol , vol.103 , pp. 100-109
  • 143
    • 77649202987 scopus 로고    scopus 로고
    • Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study
    • Pautas C, Merabet F, Thomas X, et al. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. J Clin Oncol. 2010;28:808-814
    • (2010) J Clin Oncol , vol.28 , pp. 808-814
    • Pautas, C.1    Merabet, F.2    Thomas, X.3
  • 144
    • 84873335475 scopus 로고    scopus 로고
    • Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older
    • Gardin C, Chevret S, Pautas C, et al. Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older. J Clin Oncol. 2013;31:321-327
    • (2013) J Clin Oncol , vol.31 , pp. 321-327
    • Gardin, C.1    Chevret, S.2    Pautas, C.3
  • 145
    • 73949125089 scopus 로고    scopus 로고
    • Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10
    • Mandelli F, Vignetti M, Suciu S, et al. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. J Clin Oncol. 2009;27:5397-5403
    • (2009) J Clin Oncol , vol.27 , pp. 5397-5403
    • Mandelli, F.1    Vignetti, M.2    Suciu, S.3
  • 146
    • 84863522871 scopus 로고    scopus 로고
    • Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia
    • Burnett AK, Russell NH, Hills RK, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol. 2012;30:3924-3931
    • (2012) J Clin Oncol , vol.30 , pp. 3924-3931
    • Burnett, A.K.1    Russell, N.H.2    Hills, R.K.3
  • 147
    • 84905560676 scopus 로고    scopus 로고
    • Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials
    • Hills RK, Castaigne S, Appelbaum FR, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol. 2014;15:986-996
    • (2014) Lancet Oncol , vol.15 , pp. 986-996
    • Hills, R.K.1    Castaigne, S.2    Appelbaum, F.R.3
  • 148
    • 84905560402 scopus 로고    scopus 로고
    • A new dawn for gemtuzumab ozogamicin?
    • Kharfan-Dabaja MA. A new dawn for gemtuzumab ozogamicin? Lancet Oncol. 2014;15:913-914
    • (2014) Lancet Oncol , vol.15 , pp. 913-914
    • Kharfan-Dabaja, M.A.1
  • 149
    • 84859911350 scopus 로고    scopus 로고
    • Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
    • Castaigne S, Pautas C, Terre C, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012;379:1508-1516
    • (2012) Lancet , vol.379 , pp. 1508-1516
    • Castaigne, S.1    Pautas, C.2    Terre, C.3
  • 150
    • 84861733011 scopus 로고    scopus 로고
    • Addition of gemtuzumab ozogamycin to chemotherapy improves event-free survival but not overall survival of AML patients with intermediate cytogenetics not eligible for allogeneic transplantation. Results of the GOESLAMS AML 2006 IR study
    • Delaunay J, Recher C, Pigneaux A, et al. Addition of gemtuzumab ozogamycin to chemotherapy improves event-free survival but not overall survival of AML patients with intermediate cytogenetics not eligible for allogeneic transplantation. Results of the GOESLAMS AML 2006 IR study. Blood. 2011;2011:37-38
    • (2011) Blood , vol.2011 , pp. 37-38
    • Delaunay, J.1    Recher, C.2    Pigneaux, A.3
  • 151
    • 84864063679 scopus 로고    scopus 로고
    • Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia
    • Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30:2670-2677
    • (2012) J Clin Oncol , vol.30 , pp. 2670-2677
    • Kantarjian, H.M.1    Thomas, X.G.2    Dmoszynska, A.3
  • 152
    • 84921436355 scopus 로고    scopus 로고
    • Results of a phase 3, multicenter, randomized, open-label study of azacytidine vs conventional care regimens in older patients with newly diagnosed acute myeloid leukemia [abstract]
    • Dombret H. Results of a phase 3, multicenter, randomized, open-label study of azacytidine vs conventional care regimens in older patients with newly diagnosed acute myeloid leukemia [abstract]. Haematologica. 2014;99:LB6212
    • (2014) Haematologica , vol.99 , pp. LB6212
    • Dombret, H.1
  • 153
    • 33745294373 scopus 로고    scopus 로고
    • High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: review of 3 randomized trials
    • Kern W, Estey EH. High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: review of 3 randomized trials. Cancer. 2006;107:116-124
    • (2006) Cancer , vol.107 , pp. 116-124
    • Kern, W.1    Estey, E.H.2
  • 154
    • 84897018280 scopus 로고    scopus 로고
    • High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial
    • Willemze R, Suciu S, Meloni G, et al. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial. J Clin Oncol. 2014;32:219-228
    • (2014) J Clin Oncol , vol.32 , pp. 219-228
    • Willemze, R.1    Suciu, S.2    Meloni, G.3
  • 155
    • 2342534391 scopus 로고    scopus 로고
    • Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study
    • Holowiecki J, Grosicki S, Robak T, et al. Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study. Leukemia. 2004;18:989-997
    • (2004) Leukemia , vol.18 , pp. 989-997
    • Holowiecki, J.1    Grosicki, S.2    Robak, T.3
  • 156
    • 84864039689 scopus 로고    scopus 로고
    • Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study
    • Holowiecki J, Grosicki S, Giebel S, et al. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. J Clin Oncol. 2012;30:2441-2448
    • (2012) J Clin Oncol , vol.30 , pp. 2441-2448
    • Holowiecki, J.1    Grosicki, S.2    Giebel, S.3
  • 157
    • 84894365265 scopus 로고    scopus 로고
    • Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the Medical Research Council AML15 trial
    • Burnett AK, Russell NH, Hills RK, et al. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the Medical Research Council AML15 trial. J Clin Oncol. 2013;31:3360-3368
    • (2013) J Clin Oncol , vol.31 , pp. 3360-3368
    • Burnett, A.K.1    Russell, N.H.2    Hills, R.K.3
  • 158
    • 84923620765 scopus 로고    scopus 로고
    • High-dose cytarabine consolidation (≥1.5 g/m2) might have shown a better outcomes than intermediate-dose cytarabine (1.0 g/m2) combined with anthracyclines in AML patients who had achieved complete remissions in the first induction by standard 3+7 regimen [abstract]
    • Park Y, Kang G, Kim D, et al. High-dose cytarabine consolidation (≥1.5 g/m2) might have shown a better outcomes than intermediate-dose cytarabine (1.0 g/m2) combined with anthracyclines in AML patients who had achieved complete remissions in the first induction by standard 3+7 regimen [abstract]. Blood. 2013;122:2692
    • (2013) Blood , vol.122 , pp. 2692
    • Park, Y.1    Kang, G.2    Kim, D.3
  • 159
    • 85042797200 scopus 로고    scopus 로고
    • Flai (fludarabine, cytarabine, idarubicin) plus low-dose gemtuzumab ozogamicin as induction therapy in CD33-positive AML: final results and long term outcome of a phase II multicenter clinical trial
    • Candoni A, Papayannidis C, Martinelli G, et al. Flai (fludarabine, cytarabine, idarubicin) plus low-dose gemtuzumab ozogamicin as induction therapy in CD33-positive AML: final results and long term outcome of a phase II multicenter clinical trial. Am J Hematol. 2018;93:655-663
    • (2018) Am J Hematol , vol.93 , pp. 655-663
    • Candoni, A.1    Papayannidis, C.2    Martinelli, G.3
  • 160
    • 85023622400 scopus 로고    scopus 로고
    • A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia
    • Jabbour E, Short NJ, Ravandi F, et al. A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. Cancer. 2017;123:4430-4439
    • (2017) Cancer , vol.123 , pp. 4430-4439
    • Jabbour, E.1    Short, N.J.2    Ravandi, F.3
  • 161
    • 85025432950 scopus 로고    scopus 로고
    • Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation
    • Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377:454-464
    • (2017) N Engl J Med , vol.377 , pp. 454-464
    • Stone, R.M.1    Mandrekar, S.J.2    Sanford, B.L.3
  • 162
    • 84949484439 scopus 로고    scopus 로고
    • Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
    • Rollig C, Serve H, Huttmann A, et al. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Lancet Oncol. 2015;16:1691-1699
    • (2015) Lancet Oncol , vol.16 , pp. 1691-1699
    • Rollig, C.1    Serve, H.2    Huttmann, A.3
  • 163
    • 85028038117 scopus 로고    scopus 로고
    • Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
    • Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130(suppl 1):722-731
    • (2017) Blood , vol.130 , pp. 722-731
    • Stein, E.M.1    DiNardo, C.D.2    Pollyea, D.A.3
  • 164
    • 85049221548 scopus 로고    scopus 로고
    • Ivosidenib induces durable remissions in IDH1-mutant relapsed/refractory AML
    • DiNardo CD, Stein EM, de Botton S, et al. Ivosidenib induces durable remissions in IDH1-mutant relapsed/refractory AML. N Engl J Med. 2018;378:2386-2398
    • (2018) N Engl J Med , vol.378 , pp. 2386-2398
    • DiNardo, C.D.1    Stein, E.M.2    de Botton, S.3
  • 165
    • 84994106763 scopus 로고    scopus 로고
    • Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia
    • Konopleva M, Pollyea DA, Potluri J, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6:1106-1117
    • (2016) Cancer Discov , vol.6 , pp. 1106-1117
    • Konopleva, M.1    Pollyea, D.A.2    Potluri, J.3
  • 166
    • 85042766499 scopus 로고    scopus 로고
    • Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study
    • DiNardo CD, Pratz KW, Letai A, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018;19:216-228
    • (2018) Lancet Oncol , vol.19 , pp. 216-228
    • DiNardo, C.D.1    Pratz, K.W.2    Letai, A.3
  • 167
    • 85042435982 scopus 로고    scopus 로고
    • Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors
    • Assi R, Kantarjian H, Ravandi F, Daver N. Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors. Curr Opin Hematol. 2018;25:136-145
    • (2018) Curr Opin Hematol , vol.25 , pp. 136-145
    • Assi, R.1    Kantarjian, H.2    Ravandi, F.3    Daver, N.4
  • 169
    • 85015820613 scopus 로고    scopus 로고
    • Harnessing the immune system against leukemia: monoclonal antibodies and checkpoint strategies for AML
    • Masarova L, Kantarjian H, Garcia-Mannero G, Ravandi F, Sharma P, Daver N. Harnessing the immune system against leukemia: monoclonal antibodies and checkpoint strategies for AML. Adv Exp Med Biol. 2017;995:73-95
    • (2017) Adv Exp Med Biol , vol.995 , pp. 73-95
    • Masarova, L.1    Kantarjian, H.2    Garcia-Mannero, G.3    Ravandi, F.4    Sharma, P.5    Daver, N.6
  • 170
    • 84886286103 scopus 로고    scopus 로고
    • Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia
    • Nazha A, Kantarjian H, Ravandi F, et al. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia. Am J Hematol. 2013;88:961-966
    • (2013) Am J Hematol , vol.88 , pp. 961-966
    • Nazha, A.1    Kantarjian, H.2    Ravandi, F.3
  • 171
    • 85042558672 scopus 로고    scopus 로고
    • Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes
    • Daver N, Boddu P, Garcia Manero G, et al. Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Leukemia. 2018;32:1094-1105
    • (2018) Leukemia , vol.32 , pp. 1094-1105
    • Daver, N.1    Boddu, P.2    Garcia Manero, G.3
  • 172
    • 84934441484 scopus 로고    scopus 로고
    • Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia
    • Kadia TM, Faderl S, Ravandi F, et al. Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. Cancer. 2015;121:2375-2382
    • (2015) Cancer , vol.121 , pp. 2375-2382
    • Kadia, T.M.1    Faderl, S.2    Ravandi, F.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.